<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ranitidine (United States: Withdrawn from market): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ranitidine (United States: Withdrawn from market): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ranitidine (United States: Withdrawn from market): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9853" href="/d/html/9853.html" rel="external">see "Ranitidine (United States: Withdrawn from market): Drug information"</a> and <a class="drug drug_patient" data-topicid="11022" href="/d/html/11022.html" rel="external">see "Ranitidine (United States: Withdrawn from market): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868127"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Ranitidine [DSC];</li>
<li>AG-Ranitidine [DSC];</li>
<li>APO-Ranitidine [DSC];</li>
<li>JAMP-Ranitidine;</li>
<li>M-Ranitidine [DSC];</li>
<li>MAR-Ranitidine;</li>
<li>MED Ranitidine;</li>
<li>MINT-Ranitidine;</li>
<li>PMS-Ranitidine;</li>
<li>RAN-Ranitidine;</li>
<li>RIVA-Ranitidine [DSC];</li>
<li>SANDOZ Ranitidine [DSC];</li>
<li>TEVA-Ranitidine [DSC];</li>
<li>Zantac C</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061780"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>
<div class="block don drugH1Div" id="F53462574"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note</b>
<b>: </b>As of April 2020, all prescription (including oral and injectable) and OTC ranitidine formulations have been withdrawn from the US market.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Consider judicial use in neonatal population due to an association of H<sub>2</sub> blocker use and an increased incidence of necrotizing enterocolitis (NEC) in very low birth weight (VLBW) neonates (Guillet 2006) and a reported approximate six-fold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, urinary tract infection) in VLBW neonates receiving ranitidine (Terrin 2012).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b6f688d-b859-4971-a4ae-381b861d4c4e">Gastroesophageal reflux</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux:</b>
<b>Note:</b> Routine use is not recommended in preterm neonates (AAP [Eichenwald 2018]). Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Corrected age &lt;44 weeks: Oral: 2 mg/kg/dose every 8 hours (Birch 2009; Sutphen 1989; Wheatley 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a58a2a5-0706-4b2c-9027-9b0504fa3cd0">GI bleed or stress ulcer; prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GI bleed or stress ulcer; prophylaxis:</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV:</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;37 weeks: 0.5 mg/kg/dose every 12 hours (ASHP 1999; Kuusela 1998); others have used 1.5 to 3 mg/kg/<b>day</b> divided every 12 hours (Nelson 1996).</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥37 weeks: 1.5 to 2 mg/kg/<b>day</b> in divided doses every 8 hours (Crill 1999); others have recommended higher dosing at 1.5 mg/kg/dose every 8 hours (Kuusela 1998).</p>
<p style="text-indent:-2em;margin-left:8em;">Extracorporeal membrane oxygenation (ECMO): 2 mg/kg/dose every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion:<b> Note:</b> Reported ranges are similar to the total daily dose with intermittent IV dosing.</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 1.5 mg/kg/dose, followed by usual range of 0.04 to 0.08 mg/kg/hour infusion (1 to 2 mg/kg/<b>day</b>); reported range of 0.031 to 0.125 mg/kg/hour (0.75 to 3 mg/kg/<b>day</b>); in a trial of premature neonates on concurrent dexamethasone, an infusion rate of 0.0625 mg/kg/hour was shown to maintain neonatal gastric pH &gt;4; higher rates of 0.125 mg/kg/hour have been used without additional clinical benefit (Crill 1999; Kelly 1993).</p>
<p style="text-indent:-2em;margin-left:8em;">ECMO: Term neonates: Loading dose: 2 mg/kg/dose over 10 minutes followed by 0.083 mg/kg/hour infusion (2 mg/kg/<b>day</b>), begin infusion 24 hours after loading dose; rate of infusion was increased by 0.042 mg/kg/hour (1 mg/kg/<b>day</b>) if gastric pH fell to &lt;4 (Wells 1998).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F217349"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>: </b>As of April 2020, all prescription (including oral and injectable) and OTC ranitidine formulations have been withdrawn from the US market.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76a2fd1c-1d00-48fa-8aa0-da94dac5c7ec">Duodenal or gastric ulcer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duodenal or gastric ulcer: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 4 to 8 mg/kg/day divided twice daily; maximum daily dose: 300 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 2 to 4 mg/kg/day divided every 6 to 8 hours; maximum dose: 50 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Duodenal ulcer: 150 mg twice daily <b>or</b> 300 mg once daily after the evening meal or at bedtime.</p>
<p style="text-indent:-2em;margin-left:10em;">Gastric ulcer: 150 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">IV, IM: 50 mg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years: Oral: 2 to 4 mg/kg/day once daily; maximum daily dose: 150 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;16 years: Oral: 150 mg once daily at bedtime.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce47ce73-fbfd-4c54-81d2-f67675bc530e">Erosive esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents ≤16 years: Oral: 5 to 10 mg/kg/day divided twice daily; maximum dose: 150 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;16 years: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> 150 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i> 150 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a58a2a5-0706-4b2c-9027-9b0504fa3cd0">GI bleed or stress ulcer; prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GI bleed or stress ulcer; prophylaxis:</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent IV infusion: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 2 to 6 mg/kg/day divided every 8 hours (ASHP 1999; Crill 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: 2 to 6 mg/kg/day divided every 6 hours; maximum daily dose: 300 mg/<b>day</b> (ASHP 1999; Crill 1999; Yildizdas 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous IV infusion:</i> Infants, Children, and Adolescents: Initial: 0.15 to 0.5 mg/kg/dose for 1 dose, followed by infusion of 0.08 to 0.2 mg/kg/hour (2 to 5 mg/kg/day) (Gal 2007; Lugo 2001; Osteyee 1994).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease: </b>
<b>Note: </b>Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 5 to 10 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 300 mg/<b>day</b> (AAP [Lightdale 2013]; NASPGHAN/ESPGHAN [Rosen 2018]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b24ffb30-7466-4c31-9437-62d98f7c42b8">Heartburn</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heartburn: </b>OTC labeling: <b>Note: Do not use for more than 14 days.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> Children ≥12 years and Adolescents: Oral: 75 to 150 mg 30 to 60 minutes before eating food or drinking beverages which cause heartburn; maximum daily dose: 2 doses/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relief of symptoms:</i> Children ≥12 years and Adolescents: Oral: 75 to 150 mg twice daily; maximum daily dose: 2 doses/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (eg, Zollinger-Ellison):</b>
<b>Note: </b>Proton pump inhibitors are the preferred agents (Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 g/day have been used.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if &gt;10 mEq/hour or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61e3b8cb-45d9-4d9e-908f-0d17809ef52b">Anaphylaxis, adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis, adjunct therapy:</b>
<b>Note:</b> Should not be used as monotherapy or as first-line therapy (AAAAI/ACAAI [Campbell 2014]; iCAALL [Simons 2014]; WAO [Simons 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 1 mg/kg/dose; maximum dose: 50 mg/dose (AAAAI/ACAAI [Lieberman 2010]; Canadian Paediatric Society [Cheng 2011]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159921"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents (Aronoff 2007):</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Based on a usual dose of 2 to 6 mg/kg/day divided every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: 1 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 1 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral (IV): Based on a usual dose of 2 to 4 mg/kg/day divided every 6 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: 0.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 0.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy: 1 mg/kg/dose every 12 hours.</p></div>
<div class="block dohp drugH1Div" id="F51159922"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F217326"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9853" href="/d/html/9853.html" rel="external">see "Ranitidine (United States: Withdrawn from market): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>: </b>As of April 2020, all prescription (including oral and injectable) and OTC ranitidine formulations have been withdrawn from the US market.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="326a86c2-20b8-4117-82b9-2b7b1e9d18d2">Duodenal ulcer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Duodenal ulcer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Treatment: 150 mg twice daily, or 300 mg once daily after the evening meal or at bedtime; maintenance of healing: 150 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 50 mg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent bolus or infusion: 50 mg every 6 to 8 hours (if increased doses are necessary utilize more frequent administration up to a maximum of 400 mg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 6.25 mg/hour.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ca40b5e-97eb-44ed-bd02-52d5e38a9544">Gastric ulcer, benign</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric ulcer, benign:</b>
<b>Oral:</b> 150 mg twice daily; maintenance of healing: 150 mg once daily at bedtime.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease:</b>
<b>Oral:</b> 150 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="200a8760-1690-4f53-a235-daac65cce5d9">Heartburn prevention or relief</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heartburn prevention or relief (OTC labeling):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> 75 to 150 mg 30 to 60 minutes before eating food or drinking beverages that cause heartburn (maximum: 2 doses/day); do not use for more than 14 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relief of symptoms:</i> 75 mg to 150 mg up to twice daily (maximum: 2 doses/day); do not use for more than 14 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990441"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 150 mg every 24 hours; adjust dose cautiously if needed (frequency of dosing may be increased to every 12 hours or further with caution).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 50 mg every 18 to 24 hours; adjust dose cautiously if needed</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Adjust dosing schedule so that dose is scheduled to coincide with the end of hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50987632"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F217283"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Asystole, atrioventricular block, bradycardia (with rapid IV administration), tachycardia, vasculitis, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Agitation, confusion, dizziness, depression, drowsiness, hallucination, headache, insomnia, involuntary motor activity, malaise, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Alopecia, erythema multiforme, injection site pruritus (transient), skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Acute porphyria, increased serum prolactin</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal distress, abdominal pain, constipation, diarrhea, nausea, necrotizing enterocolitis (very low weight neonates; Guillet 2006), pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, granulocytopenia, hemolytic anemia (immune; acquired), leukopenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Cholestatic hepatitis, hepatic failure, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction (eg, bronchospasm, eosinophilia, fever)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Burning sensation at injection site (transient), pain at injection site (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Acute interstitial nephritis, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pneumonia (causal relationship not established)</p></div>
<div class="block coi drugH1Div" id="F217299"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ranitidine or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to ranitidine or other acid reducers. Do not use with other acid reducers. Do not use 150 mg tablet with kidney disease without medical advice.</p></div>
<div class="block war drugH1Div" id="F217280"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Confusion: Rare cases of reversible confusion have been associated with ranitidine; usually elderly or severely ill patients, or in patients with renal or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Elevation in ALT levels has occurred with higher doses (≥100 mg) or prolonged IV therapy (≥5 days); monitor ALT levels daily for the remainder of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Prolonged treatment (≥2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (ranitidine undergoes hepatic metabolism).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Avoid use in patients with a history of acute porphyria; may precipitate attacks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Ranitidine is primarily excreted renally; dosage adjustment is recommended in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Children: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Rapid administration has been associated with bradycardia (rare), usually in patients with predisposing risk factors for cardiac rhythm disorders. Do not exceed the recommended IV administration rate(s).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syrup: May contain up to 7.5% alcohol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn longer than 3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating or pain that spreads to arms, neck, or shoulders; light-headedness. Stop use and notify health care provider if heartburn continues, worsens, or lasts longer than 14 days.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878620"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients 4 to 36 months (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with ranitidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H<sub>2</sub> blocker use and an increased incidence of necrotizing enterocolitis (NEC) in very low birth weight (VLBW) neonates (Guillet 2006). An approximate six-fold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, urinary tract infection) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates (Terrin 2012). Routine use in preterm infants is not recommended (AAP [Eichenwald 2018]). Gastric acid suppression medications, including H<sub>2</sub> blockers, have also been associated with an increase in <i>Clostridioides difficile</i> infection (CDI) and recurrent CDI in pediatric patients (Nylund 2014).</p></div>
<div class="block prod-avail drugH1Div" id="F54279480"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">As of April 2020, all prescription (including oral and injectable) and OTC ranitidine formulations have been withdrawn from the US market.</p></div>
<div class="block geq drugH1Div" id="F217276"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F217301"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (raNITIdine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (raNITIdine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/2 mL (per mL): $7.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/6 mL (per mL): $7.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/40 mL (per mL): $7.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zantac Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/2 mL (per mL): $9.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (raNITIdine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/mL (per mL): $0.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (raNITIdine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1.48 - $1.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.69 - $3.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zantac 150 Maximum Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zantac 75 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868128"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zantac C: 150 mg, 300 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg</p></div>
<div class="block admp drugH1Div" id="F52613807"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with meals and/or at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Must be diluted prior to administration; may be administered IV push, intermittent IV infusion, or continuous IV infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV infusion: Preferred over IV push to decrease risk of bradycardia; infuse over 15 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">IV push: Manufacturer recommends administering over a period of at least 5 minutes, not to exceed 10 mg/minute (4 mL/minute).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Administer at ordered rate; titration may be necessary for some conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted.</p></div>
<div class="block adm drugH1Div" id="F217296"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Injection may be administered IM or IV:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Injection is administered undiluted</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Must be diluted; may be administered intermittent bolus or intermittent IV infusion</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent bolus: Manufacturer recommends a maximum rate of administration of 10 mg/minute (infuse over at least 5 minutes); however, in adults may also be administered at a maximum rate of 25 mg/minute (or over 2 minutes) if necessary (Coursin 1988; Goelzer 1988; Smith 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Administer over a maximum rate of 2.5 to 3.5 mg/minute (infuse over at least 15 to 20 minutes)</p></div>
<div class="block uicp drugH1Div" id="F14473103"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b>  0.5 mg/mL</p></div>
<div class="block sts drugH1Div" id="F217313"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules, tablets: Store between 20°C and 25°C (68°F and 77°F). Protect from light. Protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials between 4°C and 25°C (39°F to 77°F); excursion permitted to 30°C (86°F). Protect from light; do not freeze. Avoid excessive heat (brief exposure up to 40°C does not affect the product). Undiluted solution is a clear, colorless to yellow color; slight darkening does not affect potency. Stable for 48 hours at room temperature when diluted for infusion in commonly used IV solutions (eg, NS, D5W, D10W, Ringer's lactate injection, sodium bicarbonate 5% injection).</p>
<p style="text-indent:-2em;margin-left:2em;">Syrup: Store between 20°C and 25°C (68°F and 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568668"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Short-term treatment and maintenance of healed duodenal ulcers and benign gastric ulcers, treatment of gastroesophageal reflux disease, and treatment of erosive esophagitis (All indications: FDA approved in ages ≥1 month and adults); treatment of pathologic hypersecretory conditions and maintenance of erosive esophagitis (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Relief and prevention of heartburn associated with acid indigestion and sour stomach (OTC product: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Treatment of intractable duodenal ulcers (FDA approved in ages ≥1 month and adults); treatment of pathologic hypersecretory conditions in hospitalized patients (FDA approved in adults); alternative to oral ranitidine in patients unable to take oral medication (FDA approved in ages ≥1 month and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for stress ulcer prophylaxis, upper GI bleeding, and as adjunct treatment for anaphylaxis.</p></div>
<div class="block mst drugH1Div" id="F217382"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">RaNITIdine may be confused with amantadine, riMANTAdine</p>
<p style="text-indent:-2em;margin-left:4em;">Zantac may be confused with Xanax, Zantac 360 (famotidine), Zarontin, Zofran, ZyrTEC</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F217367"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), OCT1, OCT2, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F217285"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: Give acalabrutinib capsules 2 hours before a histamine H2 receptor antagonist (H2RA). No action is required if acalabrutinib tablets are coadministered with H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Histamine H2 Receptor Antagonists may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dacomitinib.  Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Histamine H2 Receptor Antagonists may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of a histamine H2 receptor antagonist (H2RA), and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlipiZIDE: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of GlipiZIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlyBURIDE: RaNITIdine (Withdrawn from US Market) may enhance the hypoglycemic effect of GlyBURIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Infigratinib. Histamine H2 Receptor Antagonists may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with histamine receptor antagonists (H2RAs) or other gastric acid-lowering agents. If H2RAs cannot be avoided, administer infigratinib 2 hours before or 10 hours after administration of H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Histamine H2 Receptor Antagonists may increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor for reduced efficacy if concomitant use with a H2RA is required. Increases in ketoconazole dose may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir.  Management: Administer H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily simultaneously or 12 hours prior to ledipasvir. The effect of administering H2 receptor antagonists at other time intervals is unknown and  not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Histamine H2 Receptor Antagonists may decrease the absorption of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of Lomitapide.  Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent ranitidine; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of RaNITIdine (Withdrawn from US Market). Lumacaftor and Ivacaftor may increase the serum concentration of RaNITIdine (Withdrawn from US Market).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption.  Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Histamine H2 Receptor Antagonists may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib 2 hours before or 10 hours after histamine H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir.  Management: Consider alternatives to this combination for patients taking the Invirase formulation of saquinavir. No action beyond standard clinical care measures is required for patients taking the Fortovase formulation of saquinavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and H2 receptor antagonists should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 10 hours after H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: RaNITIdine (Withdrawn from US Market) may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F217316"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>
<div class="block dic drugH1Div" id="F217303"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine and/or sodium. Oral dosage forms may be taken with or without food.</p></div>
<div class="block pri drugH1Div" id="F217302"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ranitidine crosses the placenta (Armentano 1989).</p></div>
<div class="block mopp drugH1Div" id="F53568651"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, AST, ALT, renal function, gastric pH, occult blood with GI bleeding.</p></div>
<div class="block pha drugH1Div" id="F217279"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibition of histamine at H<sub>2</sub>-receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.</p></div>
<div class="block phk drugH1Div" id="F217298"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: 50%; IM: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Minimally penetrates the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants, Children, and Adolescents: IV, Oral: 1 to 2.3 L/kg </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Normal renal function: ~1.4 L/kg; CrCl 25 to 35 mL/minute: 1.76 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~15% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (minor) to N-oxide, S-oxide, and N-desmethyl metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral tablets: ~50%; IM: 90% to 100%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neonates (receiving ECMO): IV: 6.6 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants, Children, and Adolescents: IV: 1.7 to 2.4 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Oral: Normal renal function: 2.5 to 3 hours; Elderly: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">IV: Normal renal function: 2 to 2.5 hours; CrCl 25 to 35 mL/minute: 4.8 hours; Elderly: 3.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 2 to 3 hours; IM: ≤15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as unchanged drug): Oral: 30%, IV: 70%; feces (as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51220828"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma half-life, clearance, and volume of distribution are all altered in proportion to creatinine clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma half-life, clearance, and volume of distribution are all altered in proportion to creatinine clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In pediatric cardiac failure, clearance may be reduced. In a prospective population pharmacokinetic study of critically ill pediatric patients (n=78; age range: 15 days to 15.51 years), cardiac failure/surgery was found to reduce clearance by a factor of 0.463 (Hawwa 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total clearance is lowered.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F217304"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Antagonin | Apo ranitidine | Glotac | Histac | Nadine | Novo-ranidine | Pylorid | Ranacid | Ranid | Ranidine | Ranimax | Ranimed | Ranitcare | Rantag | Ranzin | Zantac</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Alivian | Dualid | Espaven | Espaven Extra Forte | Faboacid r | Fada ranitidina | Fendibina | Gastrial | Gastrosedol | Gastrozac | Labsidex | Notrab | Pylorid | Ranitic | Ranitidina celtyc | Ranitidina denver farma | Ranitidina ilab | Ranitidina lazar | Ranitidina millet | Ranitidina Pharma | Ranitidina Rigo | Ranitidina unc | Ranitidina vent 3 | Ranitral | Ranitul | Raticina | Reco | Sustac | Taural | Teogrand | Ulcotenk | Vingional | Zantac</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pylorisin | Ranic | Raninorm | Ranitidin 1a pharma gmbh | Ranitidin Accord | Ranitidin arcana | Ranitidin genericon pharma | Ranitidin Ranbaxy | Ranitidin ratiopharm | Ranitidin Sandoz | Ranitidin stada arzneihmittel gmbh | Ranityrol | Ulsal | Zantac</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acid &amp; heart burn | Amcal heartburn relief | Apo ranitidine | Apohealth ranitidine acid &amp; heartburn relief | Ausran | Biochemie heartburn relief | Cm acid&amp;heartburn | Cm ranitidine | CO Ranitidine | Dbl ranitidine | Gastrogel ranitidine | Gavilast | Gavilast 12 hour action | Heartburn relief | Medix | Mylanta | Mylanta 12 hour | Pharmacy action heartburn &amp; acid indigestion relief | Pharmacy care heartburn relief | Pharmacy health reflux relief | Rani | Ranihexal | Ranital | Ranitidine | Ranitidine an | Ranitidine gh | Ranitidine sandoz | Ranitidine-bc | Ranoxyl | Sbpa ranitidine | Tw acid&amp;h/burn rlf | Tw ranitidine | Ulcaid | Ultac | Zantac | Zantac relief</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aceptin R | Acin | Alin | Amuran | Anitid | Antac | Antamin-R | Bentid | Bitack | Centac | Ceptin r | Denitid | Denitine | Detac | Dimeran | Dugal | Duran | Editin-r | Ethidin | Exac | G-ranitidin | H blok | Hi-Tac | Inran | Inseac | Lucin-r | Lumeran | Mystin-r | Neoceptin r | Neodin | Neodin-s | Neofast-s | Neopep | Neosetin R | Neotack | Neotid | Neotidin | Neotin | Norma-H | Normacid | Off h | Ortac | Peotide | Peptidin | Peptil h | Peptosol | Protec-r | Q-ran | Radin | Ranbex | Rani | Ranicare | Ranid | Ranidin | Raniloc | Ranisis | Ranison | Ranit | Ranitab | Ranitack | Ranitec | Ranitid | Ranitidine | Ranitidine-r | Ranitor | Ranix | Rantec | Rantin | Ranul | Recodin | Redin | Reetac-R | Renicon | Rhine | Rn | Rostid | Rotid | Rt | Sutac | Tinadin | Tytac | Ulcar | Ultac | Unitac | Veridin | Wintack | Xantid | Xantid hs | Xardin | Z-ranid | Zactin | Zantac | Zenil | Zodin | Zorep | Zostac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docraniti | Pylorid | Ranitidine bexal | Ranitidine eurogenerics | Ranitidine merck-generics | Ranitidine Ratiopharm | Ranitidine sandoz | Ranitidine teva | Zantac</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Rani denk</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Histac | Raniberl | Ranitidin | Razidin | Zantac</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Antagon | Antak | Antidin | Aziliv | Bloculcer | Cloridrato de ranitidina | Ethenem | Gastak | Genotak | Iquego ranitidina | Label | Lfm ranitidina | Logat | Neosac | Nititom | Pylorid | Ramifabra | Raniclor | Ranidin | Ranidina | Ranidine | Ranidolim | Raniflex | Ranilup | Ranimax | Ranitak | Ranitidil | Ranitidina | Ranitil | Ranitinol | Ranition | Ranitrat | Ranitzen | Ranytisan | Regalil | Rhanitak | Tazepin | Tekadin | Ulcerit | Ulcerocin | Ulcoren | Zadine | Zylium</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ranimed | Ranisifar | Ranitidin cophar | Ranitidin-mepha | Zantic</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Acidac | Rani denk | Ranimat | Zynol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ranicel | Ranitax | Ranitidina | Uldine | Zantac</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dong yi | Ge lai shi | Histac | Jin de le | Lan bai xing | Ou hua da | Pylorid | Qi di | Ranitidine | Ranitidine hydrochloride and sodium chloride | Ranitidine hydrochloride in sodium chloride | Rui bei | Shan de kang | Shang wei | Xi si da | Xi si ta | Yi li shu | Zantac</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Azanplus | Clorimed | Gastrelin | Peptiran | Ragastro | Raldin | Rancet | Raniclorh | Ranidin | Ranidox | Ranimed | Raniogas | Ranipep | Raniphar | Ranisul | Raniter | Ranitidina | Ranitidina mk | Ranitil | Regastin | Reycid | Ul-pep | Ulcuran | Uldin | Ulpigas | Ultidin | Zantac</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Eradipak | Histac | Ranisan | Ranital | Ranitidine aurovitas | Ulran | Zantac</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azantac | Azuranit | Junizac | Milinda rani-nerton | Phamoranit | Ran lich | Rani | Rani biochemie | Rani nerton | Rani sanorania | Raniberl | Ranibeta | Ranibloc | Ranicux | Ranidura | Ranidura t | Raniprotect | Ranitab | Ranitic | Ranitidin | Ranitidin 1a pharma | Ranitidin atid | Ranitidin AWD | Ranitidin axsan | Ranitidin basics | Ranitidin Heumann | Ranitidin Heumann Heunet | Ranitidin ratiopharm | Ranitidin Siga | Ranitidin stada | Ranitidin-Isis | Ranitidin-saar | Ranitidoc | Raniwieb | Sostril | Zantic</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Acikure | Ranicodan | Ranitidin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apoprin | Durak | Fendibina | Pylorid | Ran H2 | Randil | Ranifur | Ranilap | Raniogas | Ranisen | Ranitidina | Ranitidina cinfa | Ranitidina normon | Taural | Tiroran | Ulciflax | Ulgasin | Ulsana | Zantac</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">It Ranichem | Libradina | Nitidan | Pylorid | Radinat | Ranicid | Raniogas | Ranitab | Ranitidina | Ranitidina genfar | Ranitidina mk | Ranitidina R | Stomacid | Taural | Tiroran | Zantac</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Kuracid | Pylorid | Raniberl | Ranideks | Ranigast | Ranisan | Ranitidin | Ranitidin alpharma | Ranitidin ratiopharm | Ranitidine accord | Zantac</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | Epiran | Gastproct | Gastroprotect | Histac | Osmoran | Pylorid | Ranicap | Ranitak | Ranitidine | Ranitidol | Rantag | Rantiblock | Rantidine | Rantidol | Zantac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arcid | Ardoral | Coralen | Denulcer | Quantor | Ran H2 | Ranidin | Ranitidina aurovitas | Ranitidina bexal | Ranitidina Edigen | Ranitidina grapa | Ranitidina grifols | Ranitidina lareq | Ranitidina mabo | Ranitidina merck | Ranitidina mundogen | Ranitidina normon | Ranitidina Pensa | Ranitidina pharmagenus | Ranitidina Ratiopharm | Ranitidina tarbis | Ranitidina Teva | Ranitidina vir | Ranix | Ranuber | Rubiulcer | Tanidina | Terposen | Toriol | Underacid | Zantac</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Rani denk | Ranitidine | Ranitol | Rantag | Zantac</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Esofex | Pylorid | Ranicur | Ranicur gerard | Ranil | Ranimex | Ranisan | Ranitidin alpharma | Ranitidin merck nm | Ranitidin pliva | Ranitidin stada | Ranitidine ranbaxy | Ranitidine sandoz | Ranixal | Zantac</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Azantac | Raniplex | Ranitidine | Ranitidine accord | Ranitidine Biogaran | Ranitidine g gam | Ranitidine gnr | Ranitidine ivax | Ranitidine merck | Ranitidine Ratiopharm | Ranitidine RPG | Ranitidine sandoz | Ranitidine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dumoran | Galpharm ranitidine | Gavilast | Gavilast-p | Heartbur antacid | Histac | Peach Ethical | Pylorid | Raciran | Ranicalm | Ranitic | Ranitidine | Ranitidine almus | Ranitidine arrow | Ranitidine cox | Ranitidine kent | Ranitidine sandoz | Ranitil | Rantec | Ranzac | Vivatak | Zaedoc | Zantac | Zantac 75</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alphadine | Aova | Baroxal | Blumol | Brixoral | Ceftrinal | Ezopta | Galebiron | Gaproxen | Lomadryl | Lumaren | Narigen | Odanet | Ptinolin | Pylorid | Raniclon | Ranitidine | Ranitidine/Generics | Ranitidine/mylan | Semuele | Smaril | Specinor | Synthomanet | Tupast | Zantac | Zoliden | Zurfix</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Eurotac | Glotac | Hyzan | Kanacid | Karitidine | Kin pak | Lumeran | Neo tac | Pylorid | Quicran | Radin | Ranatec | Randac | Ranicone | Ranidine | Ranital | Ranitid | Ranitidina cinfa | Ranitidine | Ranolta | Rantacid | Rantin | Simetac | Ulticer | Uni-Rantac | Vesyca | Weicotac | Weidos | Zantac | Zanticaine | Zantidon | Zendhin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bloculcer | Peptoran | Peptoran MAX | Ranital | Ranitidin Europharma | Ranitidin lek | Ranitidin Sandoz | Ranix | Rantin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Histac | Huma-ranidine | Pylorid | Ranitic | Ranitidin 1 A Pharma | Ranitidin-b | Ulceran | Ulcosin | Umaren | Zantac</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aciblock | Acran | Aldin | Bloxer | Chopintac forte | Conranin | Curadyn | Fordin | Gastridin | Graseric | Harmidin | Hexer | Indoran | Omeramine | Radin | Ranal | Rancus | Ranilex | Ranin | Ranitab | Ranitidin | Ranitidine | Ranivel | Ranoxin | Rantag | Ranticid | Rantin | Ratinal | Renatac | Scanarin | Titan | Tricker-150 | Tyran | Ulceranin | Uldinal | Wiacid | Xeradin | Zantac | Zantadin | Zantifar | Zenti | Zumaran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gertac | Pylorid | Ranitic | Ranitidine | Ranopine | Xanomel | Zandine | Zantac</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apozan | Zanidex | Zantab | Zantac</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | Aciran | Acirid | Agiloc | Alprodine | Alurin | Antac | Aztec | Dentac | Din | Emeltidine | Emtac | Gertac | Giran | H2loc | Healcer | Helkoss | Histac | Intac | Kamtac | Kaytec | Lydin | Monorin | Natidine | Nicotac | Nit | Peploc | R-loc | Rafilon | Rancafe | Rancer | Randinat | Ranial | Ranibid | Ranicer | Ranicom | Ranicool | Ranilink | Ranimax | Ranin | Ranipep | Ranisun | Ranit | Ranitas | Raniter | Ranitidine | Ranitidine HCL | Ranitin | Ranizac | Ranizen | Ranloc | Ranpep | Rantac | Rantica | Rd | Rdin | Relitin | Renact | Renicret | Renitab | Ridcer | Rintin | Rintric | S.tac | Saintac | Tidac | Tydin | Ulceran | Ulfast | Ultac | Ultidin | Z-ran | Zinetac | Zoran | Zynol | Zytak</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dolilux | Elicodil | Pylorid | Raniben | Ranibloc | Ranidil | Ranitidina | Ranitidina Angenerico | Ranitidina D&amp;G | Ranitidina doc | Ranitidina DRM | Ranitidina eg | Ranitidina Hexal | Ranitidina Ibirn | Ranitidina jet | Ranitidina Magis | Ranitidina Merck Generics | Ranitidina new | Ranitidina Pantafarm | Ranitidina Ranbaxy | Ranitidina sandoz | Sensigard | Ulcex | Zantac</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Antagonin | Nadine | Peptac | Pylorisin | Ranacid | Ranid | Ranidine | Zantac</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Braulibera | Hatsker | Lanizac | Lantic | Raden | Raitadin | Ranimerck | Ranitac | Ranitidine | Ranitizane | Ranitizane amel | Seochitozin | Tsurudek | Zamec | Zantac</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | Neotack | R loc | Rancer | Rani denk | Ranison | Ranitidine agio | Ranitin | Rantac | Rantag | Reducid | Renitab | Rinatadin | Ultac | Zantac | Zerocid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alsanon | Anitin | Aprogen ranitidine | Austin ranitidine hcl | Barogrin | Bc ranitidine | Bitidine | Camillan | Camilran | Celtidin | Cudin | Curan | Curitin | Curodine | Dactel | Duractin | Eltidine | Exta f | Gadin | Garantine | Gastidine | Gi-easy | Gl ranitidine | Hunitin | Huran | Hutecs ranitidine | I ran | I ranitidine | Ilyangbio ranitidine | Inotidine | Jan q pro | Jeidin | Jeil maxtidin plus | Jenitin | Jera q | Jinradine | Katiring | Keibitidine | Kms ranitidine | Kwangdong ranitidine | Kyongbo ranitidine | Locid | Luratin | Marutin | Medira | Megatin | Nelson ranitidine | Neotidine | Panstac | Pharmgen ranitidine | Ponaltin | Pylorid | Qutidin | Racidine | Radin q | Radine | Raditine | Radubadine | Ranacid | Randin | Rani s | Ranibic | Ranibig | Ranid | Ranidan | Ranidin | Ranidine | Ranidon | Ranidone | Ranikim | Raniking | Ranil | Ranis | Ranisca | Ranisen | Ranitac | Raniten | Ranitid | Ranitidine | Ranitidine hyosung | Ranitiem | Ranitigen | Ranitina | Ranition | Ranitiran gold | Ranitop | Ranix | Ranizan | Rantin | Rantine | Rantis | Raticon | Ratigen | Ratinnis | Ratudin | Renitine | Restidine | Ribotin | Rp ranitidine hcl | Rtd | Samnam ranitidine | SCD Ranitidine | Scheinedin | Tarana | Tinatin | Tinoq | Tritin | U-rantac | Ulcemed | Unidin | Urantac | Winatac | Wiradin | Wizan | Wontac | Wooritin | Xansiq | Xantas f | Youngpoong ranitidine | Yuhan ranitidine hcl | Zan q 75 | Zanci-Q | Zancid L | Zandark | Zani q | Zanstin | Zantac | Zatidine | Zellatidine | Zenitin | Zenix | Zyniq</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Glotac | Navidine | Pylorid | Ranacid | Ranid | Ranitcare | Rantag | Rantin | Zantac</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Antagonin | Glotac | Nadine | Ptinolin | Pylorid | Ranacid | Ranicux | Ranimat | Raniplex | Ranitidine | Rantag | Ulticer | Zantac</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Aciloc e | Apo ranitidine | Histac | Pylorid | Raniberl | Raniday | Ranigast | Ranisan | Ranitab | Ranital | Ranitidin | Ranitidin al | Ranitidin bp | Ranitidina normon | Ranitidine accord | Ranitidine siromed | Rantac | Ulcosan | Ulran | Zantac | Zoran</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docraniti | Pylorid | Ranitic | Ranitidine eg | Ranitidine mylan | Zantac</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Aciloc | Histac | Raniberl | Ranidex | Ranigast | Ranitab | Ranital | Ranitidin | Ranitidina | Ranitidine accord | Ranitidinum | Ranitin | Rantac | Ultak | Zantac | Zoran</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acidac | Azantac | Pylorid | Ranimat | Ranitil | Tanidine | Xanidine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acloral | Acloral b.i. | Agrisen | Alter h2 | Apodatina | Azanplus | Azantac | Azantac f | Deratin | Dinaxin | Driges | Ducan | Durak | Estoradin | Flatmed | Galidrin | Gastridin | Genotidina | Iqfadina | Katalem | Microtid | Radyn | Ranifur | Raniger | Ranisen | Ranitab | Ranitidina | Ranitidina avivia | Ranitidina gi | Ranitidina gi leme | Ranitidina gi phar | Ranitidina gi serr | Ranitidina Kendrick | Ranitidina Wermar | Ranitinida | Raudil | Redacid | Serranit | Sinhcloran | Solrasol | Syngasy | Terodul | Tianak | Tidibuffin | Ulmodhyl | Ulsaven | Unitin | Vistac</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Gastril | Histac | Hyzan | Ranitic | Ranitidine | Rantac | Rintac | Vesyca | X'tac | Xanomel | Zantac | Zendhin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | Ranivan | Softhealth ranitidine | Timetidine | Topix ranitidine | Zaridex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Azantac | Pylorid | Ranitidine | Ranitidine A | Ranitidine accord | Ranitidine cf | Ranitidine mdq | Ranitidine teva | Zantac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pylorid | Ranacid | Ranitidin | Ranitidin al | Ranitidin gea | Ranitidine | Ranitidine accord | Ranitidine rosemont | Ranitidine sandoz | Zantac | Zantac euromedica</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Arrow-ranitidine | Gavilast | Peptisoothe | Ranitidine relief | Zanidin | Zantac | Zantac relief</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Zantac</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aciflux | Atural | Galtidin | Gastriflam | Histac | Ranifur | Ranimek | Ranit | Ranitax | Ranitidina | Ulceran | Ulcip | Zantac</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amloc | Boie ranitidine | Ceranid | Contracid | Cygran | Entac | Eu-ran | Gastrone | Incid | Intac | Mordek | Pep Bloc | Peptica | Pylorid | Radine | Ramadine | Ranae | Ranid | Ranitab | Ranitein | Ranix | Rapidin | Ratidin | Raxide | Renfort | Ritemed Ranitidine | Ulcemed | Ulceragon | Ulceral | Ulcergo | Ulcerix | Ulci bloc | Ulcin | Ulzim | Zantac | Zidaxim | Zilatec</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adetac | Anzol | Certine | Dart | Degust | Dinetac | Duotec | Glamet | H2 rec | Hitac | Lomadryl | Melfax | Mifotec | Neotack | Nilcer | Nitid | Nulcer | Obatidine | Peptac | Pepticure | Peptinil | Purod | Rakitac | Ramedac | Ranacid | Ranax | Rancer | Ranidin | Ranidol | Raniloc | Ranimax | Ranimed | Ranin | Ranipep | Raniscot | Ranison | Ranizan | Rantid | Rantin | Ranulcid | Ratac | Reliance | Renacid | Renata | Renatil | Reneph | Renera | Ritadine | S cid | Stomacid | Tanidina | Ulcemed | Ulcenor | Ulcer Off | Ulcerid | Ulcetac | Ultec | Ulzan | Xancid | Xetac | Zantac | Zantidon | Zenit</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Histac | Novo-ranidine | Raniberl | Raniberl max | Ranic | Ranigast | Ranigast max | Ranigast pro | Ranimax | Ranisan | Ranital | Ranitin | Ranitydyna | Ranitydyna aurovitas | Riflux | Zantac</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acid reducer | Gabitidine | Ranitidine | Ranitidine HCL | Tritec | Zantac</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bloculcer | Gastridina | Gastrimuto | Gastrolav | Pep Rani | Peptab | Peptifar | Pylorid | Ran | Ranitidina | Stacer | Ulcecur | Zantac</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ranitidina genfar | Ranitidina vent 3 | Teogrand</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Acicare | Antagonin | Apo-Ranitidine | Glotac | Nadine | Navidine | Peptac | Qranid | Ragasit | Ranacid | Rani-nerton | Ranid | Ranidine | Ranimax AC | Ranitak | Ranitidine Mabo | Rantag | Rolan | Zantac | Zydac</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Digen | Ranitab | Ranital | Ranitidin | Ranitidin helcor | Ranitidin Ranbaxy | Ranitidina arena | Ranitidina atb | Ranitidina Laropharm | Ranitidina lph | Ranitidina slavia | Ranitin | Ulcoran | Zantac</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Aciloc e | Histac | Novo ranitidine | Pylorid | Raniberl | Ranigast | Ranisan | Ranison | Ranitab | Ranital | Ranitidin | Ranitidin akri | Ranitidin Olainfarm | Ranitidine | Ranitidine akos | Ranitidine ferein | Ranitidine lekt | Ranitin | Rantac | Rantak | Renx | Ulcodin | Zantac | Zantin | Zoran</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Acicare | Antagonin | Apo ranitidine | Glotac | Nadine | Navidine | Novo-ranidine | Peptac | Pms ranitidine | Pylorid | Ranacid | Ranid | Ranidin | Ranidine | Ranimax | Ranimax ac | Rantag | Ranzin | Tanidina | Zydac</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Artonil | Inside | Rani-q | Ranitidin actavis | Ranitidin alpharma | Ranitidin apofri | Ranitidin Hexal | Ranitidin medartuum | Ranitidin mylan | Ranitidin nm pharma | Ranitidin pliva | Ranitidin ratiopharm | Ranitidin recip | Ranitidin stada | Ranitidine ranbaxy | Zantac</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | Apo ranitidine | Histac | Hyzan | Neoceptin r | Pylorid | Radine | Rani denk | Ranidine | Ranitidina | Ranitidine | Sp-gastril | Vesyca | Xanadine | Zantac | Zendhin | Zynol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pylorid | Ranital | Ulran | Zantac</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Histac | Ranisan | Ranital | Zantac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Acicare | Aciloc | Apo ranitidine | Histac | Oltak | Pylorid | Radine | Ranicid | Ranid | Ranidine | Ranitidine | Rantac | Ranto | Rantodine | Ratic | Utac | Xanidine | Zanamet | Zantac | Zantidon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Antagonine | Tanidina</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pylorid | Ranit | Ranobel | Rozon | Ulcuran | Zandid | Zantac</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo ranitidine | Curan | Getway | Kiradin | Kowecan | Nicewe | Novo-ranidine | Quicran | Ranidine | Ranitidine | Rannine | Rnd | Sontac | Ulsafe | Vesyca | Weichilin | Weidos | Wintac | Zantac</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidex | Aciloc e | Histac | Raniberl | Ranitidin | Ranitidine | Ranitidine forte | Ranitin | Rantac | Rinit | Umetak | Zantac | Zoran</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">R loc | Rani denk</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Acigastrol | Acitran | Binacil | Binacil-s | Lunadina | Miniac | Nulacid | Ranitidina | Ranitidina lazar | Ranitidina Phs Pharmaservice | Sustac | Taural | Zantac</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aplom | Enteral | Gastac | Pylorid | Ranic | Ranitidina | Ranitidina G.C. | Ranix | Retamin | Ultidine | Vizerul | Zantac | Zoran</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Kantacid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Apex ranitidine | Apo ranitidine | Austac | Be-tabs ranitidine | Cpl alliance ranitidine | Garec-Ranitidine | Gi-tak | Gulf ranitidine | Histak | Ranihexal | Ranitidine | Ranitidine biotech | Ranteen | Simayla ranitidine | Ultak | Zantac</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aciloc | R-loc | Rani denk | Ranitin | Ranloc | Rintid | Ultac</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ranitin | Zynol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580836">
<a name="26580836"></a>American Society of Anesthesiologists. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300. doi: 10.1097/ALN.0000000000000935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/26580836/pubmed" id="26580836" target="_blank">26580836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045707">
<a name="28045707"></a>American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. <i>Anesthesiology</i>. 2017;126(3):376-393. doi: 10.1097/ALN.0000000000001452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/28045707/pubmed" id="28045707" target="_blank">28045707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690219">
<a name="10690219"></a>American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/10690219/pubmed" id="10690219" target="_blank">10690219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  APO-Ranitidine (ranitidine) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2627742">
<a name="2627742"></a>Armentano G, Bracco PL, Di Silverio C. Ranitidine in the treatment of reflux oesophagitis in pregnancy. <i>Clin Exp Obstet Gynecol</i>. 1989;16(4):130-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/2627742/pubmed" id="2627742" target="_blank">2627742</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19307225">
<a name="19307225"></a>Birch JL and Newell SJ, "Gastrooesophageal Reflux Disease in Preterm Infants: Current Management and Diagnostic Dilemmas," <i>Arch Dis Child Fetal Neonatal Ed</i>, 2009, 94(5):F379-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/19307225/pubmed" id="19307225" target="_blank">19307225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4020560">
<a name="4020560"></a>Blumer JL, Rothstein FC, Kaplan BS, et al, “Pharmacokinetic Determination of Ranitidine Pharmacodynamics in Pediatric Ulcer Disease,” <i>J Pediatr</i>, 1985, 107(2):301-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/4020560/pubmed" id="4020560" target="_blank">4020560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599–608. doi:10.1016/j.anai.2014.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635419">
<a name="12635419"></a>Cappell MS. Gastric and duodenal ulcers during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):263-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/12635419/pubmed" id="12635419" target="_blank">12635419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD and Wong B, “American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,” <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3057942">
<a name="3057942"></a>Coursin DB, Farin-Rusk C, Springman SR, et al, “The Hemodynamic Effects of Intravenous Cimetidine versus Ranitidine in Intensive Care Unit Patients: A Double-Blind, Prospective, Cross-Over Study,” <i>Anesthesiology</i>, 1988, 69(6):975-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/3057942/pubmed" id="3057942" target="_blank">3057942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10030767">
<a name="10030767"></a>Crill CM and Hak EB, "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients," <i>Pharmacotherapy</i>, 1999, 19(2):162-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/10030767/pubmed" id="10030767" target="_blank">10030767</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Eddleston JM, Booker PD, and Green JR, “Use of Ranitidine in Children Undergoing Cardiopulmonary Bypass,” <i>Crit Care Med</i>, 1989, 17(1):26-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/ 2909317 /pubmed" id=" 2909317 " target="_blank"> 2909317 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC; Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants [published online July 2, 2018]. <i>Pediatrics</i>. 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8323366">
<a name="8323366"></a>Fontana M, Massironi E, Rossi A, et al, “Ranitidine Pharmacokinetics in Newborn Infants,” <i>Arch Dis Child</i>, 1993, 68(5 Spec No):602-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/8323366/pubmed" id="8323366" target="_blank">8323366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3276451">
<a name="3276451"></a>Goelzer SL, Farin-Rusk C, and Coursin DB, “Ranitidine Produces Minimal Hemodynamic Depression in Stable Intensive Care Unit Patients: A Double-Blind, Prospective Study,” <i>Crit Care Med</i>, 1988, 16(1):8-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/3276451/pubmed" id="3276451" target="_blank">3276451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29019150">
<a name="29019150"></a>Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE Group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? <i>Endocrine</i>. 2018;60(1):15-27. doi: 10.1007/s12020-017-1420-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/29019150/pubmed" id="29019150" target="_blank">29019150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390920">
<a name="16390920"></a>Guillet R, Stoll BJ, Cotten CM, et al, "Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants," <i>Pediatrics</i>, 2006, 117(2):137-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/16390920/pubmed" id="16390920" target="_blank">16390920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23016949">
<a name="23016949"></a>Hawwa AF, Westwood PM, Collier PS, et al. Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. <i>Br J Clin Pharmacol</i>. 2013;75(5):1265-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/23016949/pubmed" id="23016949" target="_blank">23016949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23363383">
<a name="23363383"></a>Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. <i>Expert Opin Pharmacother</i>. 2013;14(3):307-321. doi: 10.1517/14656566.2013.767332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/23363383/pubmed" id="23363383" target="_blank">23363383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease [published correction appears in <i>Am J Gastroenterol</i>. 2013;108(10):1672]. <i>Am J Gastroenterol</i>. 2013;108(3):308-328. doi: 10.1038/ajg.2012.444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4039999">
<a name="4039999"></a>Kearns GL, McConnell RF Jr, Trang JM, Kluza RB. Appearance of ranitidine in breast milk following multiple dosing. <i>Clin Pharm</i>. 1985;4(3):322-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/4039999/pubmed" id="4039999" target="_blank">4039999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8346951">
<a name="8346951"></a>Kelly EJ, Chatfield SL, Brownlee KG, et al, "The Effect of Intravenous Ranitidine on the Intragastric pH of Preterm Infants Receiving Dexamethasone," <i>Arch Dis Child</i>, 1993, 69(1 Spec No):37-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/8346951/pubmed" id="8346951" target="_blank">8346951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9577289">
<a name="9577289"></a>Kuusela AL, "Long-Term Gastric pH Monitoring for Determining Optimal Dose of Ranitidine for Critically Ill Preterm and Term Neonates," <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 78(2):F151-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/9577289/pubmed" id="9577289" target="_blank">9577289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20692689">
<a name="20692689"></a>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update [published correction appears in <i>J Allergy Clin Immunol</i>. 2010;126(6):1104]. <i>J Allergy Clin Immunol</i>. 2010;126(3):477-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/20692689/pubmed" id="20692689" target="_blank">20692689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lopez-Herce J, Albajara L, Codoceo R, et al, “Ranitidine Prophylaxis in Acute Gastric Mucosal Damage in Critically Ill Pediatric Patients,” <i>Crit Care Med</i>, 1988, 16(6):591-93.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11373465">
<a name="11373465"></a>Lugo RA, Harrison AM, Cash J, Sweeley J, Vernon DD. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. <i>Crit Care Med</i>. 2001;29(4):759-764.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/11373465/pubmed" id="11373465" target="_blank">11373465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-84.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7920954">
<a name="7920954"></a>Osteyee JL, Banner W Jr. Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children. <i>Am J Crit Care</i>. 1994;3(4):267-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/7920954/pubmed" id="7920954" target="_blank">7920954</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ranitidine capsules and tablets [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc; March 2019.</div>
</li>
<li>
<div class="reference">
                  Ranitidine injection [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc; June 2018.</div>
</li>
<li>
<div class="reference">
                  Ranitidine syrup [prescribing information]. Carmel, NY: Silarx Pharmaceutical Inc; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635418">
<a name="12635418"></a>Richter JE, “Gastroesophageal Reflux Disease During Pregnancy,” <i>Gastroenterol Clin North Am</i>, 2003, 32(1):235-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/12635418/pubmed" id="12635418" target="_blank">12635418</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Riley AJ, Crowley P, Harrison C. Transfer of ranitidine to biological fluids: milk and semen. In: Misiewicz JJ, Wormsley KG, eds. The clinical use of ranitidine. Oxford: Medicine Publishing Foundation, 1982:78-81. As reported by LACTMED: <a href="https://www.ncbi.nlm.nih.gov/books/NBK501252/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK501252/</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6329583">
<a name="6329583"></a>Roberts CJ, “Clinical Pharmacokinetics of Ranitidine,” <i>Clin Pharmacokinet</i>, 1984, 9(3):211-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/6329583/pubmed" id="6329583" target="_blank">6329583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24920969">
<a name="24920969"></a>Simons FE, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. <i>World Allergy Organ J</i>. 2014;7(1):9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/24920969/pubmed" id="24920969" target="_blank">24920969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3689613">
<a name="3689613"></a>Smith CL, Bardgett DM, and Hunter JM, “Haemodynamic Effects of the I.V. Administration of Cimetidine or Ranitidine in the Critically Ill Patient: A Double-Blind Prospective Study,” Br J Anaesth, 1987, 59(11):1397-1402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/3689613/pubmed" id="3689613" target="_blank">3689613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2921693">
<a name="2921693"></a>Sutphen JL and Dillard VL, "Effect of Ranitidine on Twenty-Four-Hour Gastric Acidity in Infants," <i>J Pediatr</i>, 1989, 114(3):472-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/2921693/pubmed" id="2921693" target="_blank">2921693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157140">
<a name="22157140"></a>Terrin G, Passariello A, De Curtis M, et al, "Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns," <i>Pediatrics</i>, 2012, 129(1):40-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/22157140/pubmed" id="22157140" target="_blank">22157140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9602950">
<a name="9602950"></a>Wells TG, Heulitt MJ, Taylor BJ, et al, "Pharmacokinetics and Pharmacodynamics of Ranitidine in Neonates Treated With Extracorporeal Membrane Oxygenation," <i>J Clin Pharmacol</i>, 1998, 38(5):402-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/9602950/pubmed" id="9602950" target="_blank">9602950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19540518">
<a name="19540518"></a>Wheatley E and Kennedy KA, "Cross-Over Trial of Treatment for Bradycardia Attributed to Gastroesophageal Reflux in Preterm Infants," <i>J Pediatr</i>, 2009, 155(4):516-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/19540518/pubmed" id="19540518" target="_blank">19540518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12501151">
<a name="12501151"></a>Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. <i>J Crit Care</i>. 2002;17(4):240-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranitidine-united-states-withdrawn-from-market-pediatric-drug-information/abstract-text/12501151/pubmed" id="12501151" target="_blank">12501151</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2013.</div>
</li>
<li>
<div class="reference">
                  Zantac 150 tablets (ranitidine) [prescribing information]. Chattanooga, TN: Chattem, Inc; received September 2019.</div>
</li>
<li>
<div class="reference">
                  Zantac 150 and 300 tablets (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2016.</div>
</li>
<li>
<div class="reference">
                  Zantac 150 and 300 tablets (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2018.</div>
</li>
<li>
<div class="reference">
                  Zantac 75 tablets (ranitidine) [prescribing information]. Chattanooga, TN: Chattem, Inc; received September 2019.</div>
</li>
<li>
<div class="reference">
                  Zantac injection (ranitidine) [prescribing information]. Buena, NJ: Teligent Pharma Inc.; September 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12759 Version 527.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
